- Home
- ITRM vs SDST Comparison
ITRM vs SDST Comparison
Compare ITRM & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- SDST
- Stock Information
- Founded
- ITRM 2015
- SDST 2022
- Country
- ITRM Ireland
- SDST United States
- Employees
- ITRM N/A
- SDST 8
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- SDST Blank Checks
- Sector
- ITRM Health Care
- SDST Finance
- Exchange
- ITRM Nasdaq
- SDST Nasdaq
- Market Cap
- ITRM 37.7M
- SDST 36.4M
- IPO Year
- ITRM 2018
- SDST N/A
- Fundamental
- Price
- ITRM $1.30
- SDST $0.52
- Analyst Decision
- ITRM Strong Buy
- SDST Strong Buy
- Analyst Count
- ITRM 1
- SDST 2
- Target Price
- ITRM $5.00
- SDST $1.73
- AVG Volume (30 Days)
- ITRM 364.7K
- SDST 249.0K
- Earning Date
- ITRM 05-12-2025
- SDST 05-15-2025
- Dividend Yield
- ITRM N/A
- SDST N/A
- EPS Growth
- ITRM N/A
- SDST N/A
- EPS
- ITRM N/A
- SDST N/A
- Revenue
- ITRM N/A
- SDST N/A
- Revenue This Year
- ITRM N/A
- SDST $4,114.37
- Revenue Next Year
- ITRM $150.10
- SDST N/A
- P/E Ratio
- ITRM N/A
- SDST N/A
- Revenue Growth
- ITRM N/A
- SDST N/A
- 52 Week Low
- ITRM $0.81
- SDST $0.41
- 52 Week High
- ITRM $3.02
- SDST $28.38
- Technical
- Relative Strength Index (RSI)
- ITRM 56.35
- SDST N/A
- Support Level
- ITRM $1.01
- SDST N/A
- Resistance Level
- ITRM $1.42
- SDST N/A
- Average True Range (ATR)
- ITRM 0.09
- SDST 0.00
- MACD
- ITRM 0.03
- SDST 0.00
- Stochastic Oscillator
- ITRM 73.17
- SDST 0.00
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).